Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancer Biomarkers : Section a of Disease Markers|May 25, 2007
Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanomaTanja Rothhammer, Peter J Wild, Stefanie Meyer, et al.
BMC Cancer|May 5, 2018
Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditionsMarkus Schulze, Maria Hutterer, Anja Sabo, et al.
Oncotarget|October 10, 2015
TGF-ß isoforms in cancer: Immunohistochemical expression and Smad-pathway-activity-analysis in thirteen major tumor types with a critical appraisal of antibody specificity and immunohistochemistry assay validityMarkus J Riemenschneider, Maria Hirblinger, Arabel Vollmann-Zwerenz, et al.
Acta Neuropathologica Communications|August 8, 2020
A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncologyJulia Lorenz, Tanja Rothhammer-Hampl, Saida Zoubaa, et al.
Clinical Neuropathology|May 1, 2020
Quality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019Markus J Riemenschneider, Josephine Fischer, Maja Grassow-Narlik, et al.
Cells|July 29, 2023
Scaffold-Based (Matrigel™) 3D Culture Technique of Glioblastoma Recovers a Patient-like Immunosuppressive PhenotypeFrank K Braun, Tanja Rothhammer-Hampl, Julia Lorenz, et al.
Molecular Psychiatry|June 22, 2022
Induced neural progenitor cells and iPS-neurons from major depressive disorder patients show altered bioenergetics and electrophysiological propertiesJulian Triebelhorn, Iseline Cardon, Kerstin Kuffner, et al.
Clinical Neuropathology|March 31, 2023
Update on quality assurance in neuropathology: Summary of the round robin trials on TERT promoter mutation, H3-3A mutation, 1p/19q codeletion, and KIAA1549::BRAF fusion testing in Germany in 2020 and 2021Sandra Pohl, Lora Dimitrova, Maja Grassow-Narlik, et al.
International Journal of Molecular Sciences|October 14, 2022
Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal OriginCorinna Seliger, Anne-Louise Meyer, Verena Leidgens, et al.
Acta Neuropathologica Communications|September 11, 2023
Translocator protein (18kDA) (TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophagesLorraine Weidner, Julia Lorenz, Stefanie Quach, et al.
Pageof 3